アンチセンスオリゴヌクレオチド（ASO）治療薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Antisense Oligonucleotide (ASO) Therapeutics Market Insights, Forecast to 2028

• レポートコード：QY2207E09222 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界のアンチセンスオリゴヌクレオチド（ASO）治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にアンチセンスオリゴヌクレオチド（ASO）治療薬の世界市場のxxx％を占める「肺内投与」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「遺伝子疾患」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のアンチセンスオリゴヌクレオチド（ASO）治療薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのアンチセンスオリゴヌクレオチド（ASO）治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 アンチセンスオリゴヌクレオチド（ASO）治療薬のグローバル主要メーカーには、Ionis Pharmaceuticals, Inc、Sarpeta Therapeutics Inc.、Biogen Inc、Alnylam Pharmaceuticals, Inc、Antisense Therapeutics Limited、Arrowhead Pharmaceuticals Inc.、Enzon Pharmaceuticals, Inc.、Bio-Path Holdings, Inc.、GlaxoSmithKline PLC、Geron Corporation (Geron)などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 アンチセンスオリゴヌクレオチド（ASO）治療薬市場は、種類と用途によって区分されます。世界のアンチセンスオリゴヌクレオチド（ASO）治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 肺内投与、静脈内投与、皮内投与、腹腔内投与、局所投与、その他 【用途別セグメント】 遺伝子疾患、神経疾患、腫瘍疾患、代謝疾患、眼科疾患、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - アンチセンスオリゴヌクレオチド（ASO）治療薬製品概要 - 種類別市場（肺内投与、静脈内投与、皮内投与、腹腔内投与、局所投与、その他） - 用途別市場（遺伝子疾患、神経疾患、腫瘍疾患、代謝疾患、眼科疾患、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のアンチセンスオリゴヌクレオチド（ASO）治療薬販売量予測2017-2028 - 世界のアンチセンスオリゴヌクレオチド（ASO）治療薬売上予測2017-2028 - アンチセンスオリゴヌクレオチド（ASO）治療薬の地域別販売量 - アンチセンスオリゴヌクレオチド（ASO）治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別アンチセンスオリゴヌクレオチド（ASO）治療薬販売量 - 主要メーカー別アンチセンスオリゴヌクレオチド（ASO）治療薬売上 - 主要メーカー別アンチセンスオリゴヌクレオチド（ASO）治療薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（肺内投与、静脈内投与、皮内投与、腹腔内投与、局所投与、その他） - アンチセンスオリゴヌクレオチド（ASO）治療薬の種類別販売量 - アンチセンスオリゴヌクレオチド（ASO）治療薬の種類別売上 - アンチセンスオリゴヌクレオチド（ASO）治療薬の種類別価格 ・用途別市場規模（遺伝子疾患、神経疾患、腫瘍疾患、代謝疾患、眼科疾患、その他） - アンチセンスオリゴヌクレオチド（ASO）治療薬の用途別販売量 - アンチセンスオリゴヌクレオチド（ASO）治療薬の用途別売上 - アンチセンスオリゴヌクレオチド（ASO）治療薬の用途別価格 ・北米市場 - 北米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（種類別、用途別） - 主要国別のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（種類別、用途別） - 主要国別のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（種類別、用途別） - 主要国別のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（種類別、用途別） - 主要国別のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（種類別、用途別） - 主要国別のアンチセンスオリゴヌクレオチド（ASO）治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Ionis Pharmaceuticals, Inc、Sarpeta Therapeutics Inc.、Biogen Inc、Alnylam Pharmaceuticals, Inc、Antisense Therapeutics Limited、Arrowhead Pharmaceuticals Inc.、Enzon Pharmaceuticals, Inc.、Bio-Path Holdings, Inc.、GlaxoSmithKline PLC、Geron Corporation (Geron) ・産業チェーン及び販売チャネル分析 - アンチセンスオリゴヌクレオチド（ASO）治療薬の産業チェーン分析 - アンチセンスオリゴヌクレオチド（ASO）治療薬の原材料 - アンチセンスオリゴヌクレオチド（ASO）治療薬の生産プロセス - アンチセンスオリゴヌクレオチド（ASO）治療薬の販売及びマーケティング - アンチセンスオリゴヌクレオチド（ASO）治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - アンチセンスオリゴヌクレオチド（ASO）治療薬の産業動向 - アンチセンスオリゴヌクレオチド（ASO）治療薬のマーケットドライバー - アンチセンスオリゴヌクレオチド（ASO）治療薬の課題 - アンチセンスオリゴヌクレオチド（ASO）治療薬の阻害要因 ・主な調査結果

Market Analysis and Insights: Global Antisense Oligonucleotide (ASO) Therapeutics Market
The global Antisense Oligonucleotide (ASO) Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Pulmonary Delivery accounting for % of the Antisense Oligonucleotide (ASO) Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Genetic Disorders segment is altered to an % CAGR throughout this forecast period.
China Antisense Oligonucleotide (ASO) Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Antisense Oligonucleotide (ASO) Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antisense Oligonucleotide (ASO) Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antisense Oligonucleotide (ASO) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antisense Oligonucleotide (ASO) Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antisense Oligonucleotide (ASO) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antisense Oligonucleotide (ASO) Therapeutics market.
Global Antisense Oligonucleotide (ASO) Therapeutics Scope and Market Size
Antisense Oligonucleotide (ASO) Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antisense Oligonucleotide (ASO) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Pulmonary Delivery
Intravenous Injections
Intradermal Injections
Intraperitoneal Injections
Topical Delivery
Others
Segment by Application
Genetic Disorders
Neurological Disorders
Oncological Disorders
Metabolic Disorders
Ophthalmic Disorders
Others
By Company
Ionis Pharmaceuticals, Inc
Sarpeta Therapeutics Inc.
Biogen Inc
Alnylam Pharmaceuticals, Inc
Antisense Therapeutics Limited
Arrowhead Pharmaceuticals Inc.
Enzon Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
GlaxoSmithKline PLC
Geron Corporation (Geron)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

---

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Pulmonary Delivery
1.2.3 Intravenous Injections
1.2.4 Intradermal Injections
1.2.5 Intraperitoneal Injections
1.2.6 Topical Delivery
1.2.7 Others
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Genetic Disorders
1.3.3 Neurological Disorders
1.3.4 Oncological Disorders
1.3.5 Metabolic Disorders
1.3.6 Ophthalmic Disorders
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Perspective (2017-2028)
2.2 Antisense Oligonucleotide (ASO) Therapeutics Growth Trends by Region
2.2.1 Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Antisense Oligonucleotide (ASO) Therapeutics Market Dynamics
2.3.1 Antisense Oligonucleotide (ASO) Therapeutics Industry Trends
2.3.2 Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
2.3.3 Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
2.3.4 Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue
3.1.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antisense Oligonucleotide (ASO) Therapeutics Revenue
3.4 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2021
3.5 Antisense Oligonucleotide (ASO) Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense Oligonucleotide (ASO) Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense Oligonucleotide (ASO) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Type
4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Application
5.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
6.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type
6.2.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type (2017-2028)
6.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application
6.3.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application (2017-2028)
6.4 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country
6.4.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
7.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type
7.2.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type (2017-2028)
7.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application
7.3.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application (2017-2028)
7.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country
7.4.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
9.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type
9.2.1 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application
9.3.1 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country
9.4.1 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals, Inc
11.1.1 Ionis Pharmaceuticals, Inc Company Details
11.1.2 Ionis Pharmaceuticals, Inc Business Overview
11.1.3 Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.1.4 Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.1.5 Ionis Pharmaceuticals, Inc Recent Developments
11.2 Sarpeta Therapeutics Inc.
11.2.1 Sarpeta Therapeutics Inc. Company Details
11.2.2 Sarpeta Therapeutics Inc. Business Overview
11.2.3 Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.2.4 Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.2.5 Sarpeta Therapeutics Inc. Recent Developments
11.3 Biogen Inc
11.3.1 Biogen Inc Company Details
11.3.2 Biogen Inc Business Overview
11.3.3 Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.3.4 Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.3.5 Biogen Inc Recent Developments
11.4 Alnylam Pharmaceuticals, Inc
11.4.1 Alnylam Pharmaceuticals, Inc Company Details
11.4.2 Alnylam Pharmaceuticals, Inc Business Overview
11.4.3 Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.4.4 Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.4.5 Alnylam Pharmaceuticals, Inc Recent Developments
11.5 Antisense Therapeutics Limited
11.5.1 Antisense Therapeutics Limited Company Details
11.5.2 Antisense Therapeutics Limited Business Overview
11.5.3 Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.5.4 Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.5.5 Antisense Therapeutics Limited Recent Developments
11.6 Arrowhead Pharmaceuticals Inc.
11.6.1 Arrowhead Pharmaceuticals Inc. Company Details
11.6.2 Arrowhead Pharmaceuticals Inc. Business Overview
11.6.3 Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.6.4 Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.6.5 Arrowhead Pharmaceuticals Inc. Recent Developments
11.7 Enzon Pharmaceuticals, Inc.
11.7.1 Enzon Pharmaceuticals, Inc. Company Details
11.7.2 Enzon Pharmaceuticals, Inc. Business Overview
11.7.3 Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.7.4 Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.7.5 Enzon Pharmaceuticals, Inc. Recent Developments
11.8 Bio-Path Holdings, Inc.
11.8.1 Bio-Path Holdings, Inc. Company Details
11.8.2 Bio-Path Holdings, Inc. Business Overview
11.8.3 Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.8.4 Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.8.5 Bio-Path Holdings, Inc. Recent Developments
11.9 GlaxoSmithKline PLC
11.9.1 GlaxoSmithKline PLC Company Details
11.9.2 GlaxoSmithKline PLC Business Overview
11.9.3 GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.9.4 GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.9.5 GlaxoSmithKline PLC Recent Developments
11.10 Geron Corporation (Geron)
11.10.1 Geron Corporation (Geron) Company Details
11.10.2 Geron Corporation (Geron) Business Overview
11.10.3 Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.10.4 Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.10.5 Geron Corporation (Geron) Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Pulmonary Delivery
Table 3. Key Players of Intravenous Injections
Table 4. Key Players of Intradermal Injections
Table 5. Key Players of Intraperitoneal Injections
Table 6. Key Players of Topical Delivery
Table 7. Key Players of Others
Table 8. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 9. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 10. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 11. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2017-2022)
Table 12. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 13. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2023-2028)
Table 14. Antisense Oligonucleotide (ASO) Therapeutics Market Trends
Table 15. Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
Table 16. Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
Table 17. Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
Table 18. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 19. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Share by Players (2017-2022)
Table 20. Global Top Antisense Oligonucleotide (ASO) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2021)
Table 21. Ranking of Global Top Antisense Oligonucleotide (ASO) Therapeutics Companies by Revenue (US$ Million) in 2021
Table 22. Global 5 Largest Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Antisense Oligonucleotide (ASO) Therapeutics Product Solution and Service
Table 25. Date of Enter into Antisense Oligonucleotide (ASO) Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 28. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2017-2022)
Table 29. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 30. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2023-2028)
Table 31. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 32. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Share by Application (2017-2022)
Table 33. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 34. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Share by Application (2023-2028)
Table 35. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 36. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 37. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 38. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 39. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 40. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 41. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 42. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 43. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 44. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 45. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 46. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 47. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 48. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 49. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 50. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 51. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 52. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 53. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 54. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 55. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 56. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 57. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 58. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 63. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 64. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 65. Ionis Pharmaceuticals, Inc Company Details
Table 66. Ionis Pharmaceuticals, Inc Business Overview
Table 67. Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 68. Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Ionis Pharmaceuticals, Inc Recent Developments
Table 70. Sarpeta Therapeutics Inc. Company Details
Table 71. Sarpeta Therapeutics Inc. Business Overview
Table 72. Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 73. Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Sarpeta Therapeutics Inc. Recent Developments
Table 75. Biogen Inc Company Details
Table 76. Biogen Inc Business Overview
Table 77. Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 78. Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Biogen Inc Recent Developments
Table 80. Alnylam Pharmaceuticals, Inc Company Details
Table 81. Alnylam Pharmaceuticals, Inc Business Overview
Table 82. Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 83. Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Alnylam Pharmaceuticals, Inc Recent Developments
Table 85. Antisense Therapeutics Limited Company Details
Table 86. Antisense Therapeutics Limited Business Overview
Table 87. Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Product
Table 88. Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 89. Antisense Therapeutics Limited Recent Developments
Table 90. Arrowhead Pharmaceuticals Inc. Company Details
Table 91. Arrowhead Pharmaceuticals Inc. Business Overview
Table 92. Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 93. Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Arrowhead Pharmaceuticals Inc. Recent Developments
Table 95. Enzon Pharmaceuticals, Inc. Company Details
Table 96. Enzon Pharmaceuticals, Inc. Business Overview
Table 97. Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 98. Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 99. Enzon Pharmaceuticals, Inc. Recent Developments
Table 100. Bio-Path Holdings, Inc. Company Details
Table 101. Bio-Path Holdings, Inc. Business Overview
Table 102. Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 103. Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 104. Bio-Path Holdings, Inc. Recent Developments
Table 105. GlaxoSmithKline PLC Company Details
Table 106. GlaxoSmithKline PLC Business Overview
Table 107. GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Product
Table 108. GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 109. GlaxoSmithKline PLC Recent Developments
Table 110. Geron Corporation (Geron) Company Details
Table 111. Geron Corporation (Geron) Business Overview
Table 112. Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Product
Table 113. Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 114. Geron Corporation (Geron) Recent Developments
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Pulmonary Delivery Features
Figure 3. Intravenous Injections Features
Figure 4. Intradermal Injections Features
Figure 5. Intraperitoneal Injections Features
Figure 6. Topical Delivery Features
Figure 7. Others Features
Figure 8. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application: 2021 VS 2028
Figure 9. Genetic Disorders Case Studies
Figure 10. Neurological Disorders Case Studies
Figure 11. Oncological Disorders Case Studies
Figure 12. Metabolic Disorders Case Studies
Figure 13. Ophthalmic Disorders Case Studies
Figure 14. Others Case Studies
Figure 15. Antisense Oligonucleotide (ASO) Therapeutics Report Years Considered
Figure 16. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 17. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region: 2021 VS 2028
Figure 19. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Players in 2021
Figure 20. Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2021
Figure 22. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 23. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 24. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 25. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Share by Country (2017-2028)
Figure 26. United States Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Canada Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 29. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 30. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 31. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Share by Country (2017-2028)
Figure 32. Germany Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. France Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. U.K. Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Italy Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Russia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Nordic Countries Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 39. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 40. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 41. Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Share by Region (2017-2028)
Figure 42. China Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Japan Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. India Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Australia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 48. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 50. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 51. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Share by Country (2017-2028)
Figure 52. Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 55. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Type (2017-2028)
Figure 56. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size Market Share by Application (2017-2028)
Figure 57. Middle East and Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size Share by Country (2017-2028)
Figure 58. Turkey Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 59. Saudi Arabia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 60. UAE Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 61. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 62. Sarpeta Therapeutics Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 63. Biogen Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 64. Alnylam Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 65. Antisense Therapeutics Limited Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 66. Arrowhead Pharmaceuticals Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 67. Enzon Pharmaceuticals, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 68. Bio-Path Holdings, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 69. GlaxoSmithKline PLC Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 70. Geron Corporation (Geron) Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

---